Abeona Therapeutics Inc. (ABEO) Dividend History

Company News

• US FDA Orphan Drug Rare Disease Market Clinical Trials Drug Sales Insight 2030

  The report provides detailed insights into the US orphan drug market, highlighting the significant growth opportunity of over $190 billion by 2030. It covers over 1,400 FDA-designated orphan drugs, including their clinical trials, pricing, dosage, and sales data.

  GlobeNewswire Inc.
• U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

  The U.S. FDA has approved ZEVASKYN, the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and debilitating genetic skin disease. ZEVASKYN has demonstrated clinically meaningful wound healing and pain reduction with a single surgical application.

  GlobeNewswire Inc.
• Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight

  The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.

  GlobeNewswire Inc.

  Featured Companies: BCLI CAPR EDIT FDMT FOLD OCGN PFE RARE RGNX SGMO
• Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI

  The global mucopolysaccharidosis treatment market is expected to grow significantly, driven by advancements in biotechnology, improved diagnostic techniques, and increased awareness of rare diseases. The market is projected to reach $5,014.5 million by 2035, growing at a CAGR of 5.9%.

  GlobeNewswire Inc.

  Featured Companies: BMRN RARE RGNX SGMO SRPT
• Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  CLEVELAND, June 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

  GlobeNewswire Inc.